May 2020

Presentations

Brentuximab Vedotin | Lymphoma | Abstract TPS8069​

Frontline brentuximab vedotin in Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma for older patients and those with comorbidities​

Brentuximab Vedotin | Lymphoma | Abstract 8032

Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients

Brentuximab Vedotin | Lymphoma | Abstract 8013

Nivolumab and brentuximab vedotin (BV) based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis

Brentuximab Vedotin | Lymphoma | Abstract TPS8068

Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced stage Hodgkin lymphoma (Trial in Progress)

Enfortumab Vedotin | Urothelial Carcinoma | Abstract 5044

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS5092

Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab for locally advanced or metastatic urothelial carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract TPS3647

EV-202: A Phase 2 Study of Enfortumab Vedotin in Patients With Select Previously Treated Locally Advanced or Metastatic Solid Tumors

Tucatinib | Breast Cancer | Abstract 1043/128

Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)

Tucatinib | Breast Cancer | Abstract 1005

Tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)

Tisotumab Vedotin | Cervical Cancer | Abstract TPS6095

Phase 1b/2 trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024)

Ladiratuzumab Vedotin | Breast Cancer | TPS1104

SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer

SGN-CD228A | Solid Tumors | Abstract TPS3652

SGN228-001: A phase 1 open-label dose escalation and expansion study of SGN-CD228A in select advanced solid tumors

SEA-CD40 | Pancreatic Cancer | Abstract TPS4671

Phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC)

Videos

Tucatinib | Breast Cancer | Abstract 1005

Tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)

 

Tucatinib | Breast Cancer | Abstract 1043/128

Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)